Clinical bottom line
Modulation of the gut microbiome represents a promising adjunctive strategy to reduce disease activity in rheumatoid arthritis (RA). Emerging evidence suggests that dietary interventions, phenolic compounds, and targeted microbiota modulation can influence immune-inflammatory pathways implicated in RA pathogenesis. However, clinical data remain preliminary, and standardized protocols for microbiome-based therapies are lacking.
What the evidence shows
The gut microbiota plays a critical role in immune regulation, with dysbiosis linked to RA development and progression. Direito et al. (2021) reviewed phenolic compounds’ impact on RA and inflammatory bowel disease, highlighting their ability to modulate gut microbiota composition and reduce systemic inflammation through antioxidant and anti-inflammatory effects.
Chasov et al. (2024) discussed gut microbiota modulation as a novel therapeutic approach in RA, emphasizing probiotics, prebiotics, and dietary modifications that may restore microbial balance and attenuate autoimmune responses.
Martinelli et al. (2024) explored the complex interactions among microbiota, immunity, and hormones in autoimmune diseases, underscoring how microbiome alterations can influence disease activity and suggesting potential for personalized interventions.
Rodziewicz et al. (2026) presented recent data linking diet-induced microbiome changes to immune-inflammatory status and RA disease activity, advocating for integrative management incorporating nutritional strategies.
Hansen et al. (2025) reviewed fasting and caloric restriction effects on RA, reporting improvements in clinical symptoms potentially mediated by microbiome shifts and reduced pro-inflammatory cytokines.
Disease activity measurement remains essential to assess intervention impact. Established indices such as DAS28 and CDAI provide standardized assessment frameworks (Anderson et al., 2011; Fransen et al., 2003).
Caveats and uncertainty
Most evidence is derived from preclinical studies, small cohorts, or narrative reviews, limiting clinical applicability.
Heterogeneity in microbiome composition and patient responses complicates treatment standardization.
Long-term safety and efficacy of microbiome-targeted therapies in RA are not well established.
Confounding factors such as concomitant medications and lifestyle may influence outcomes.
Optimal microbial targets and intervention timing remain undefined.
How this may change practice
Clinicians should consider the potential role of microbiome modulation as an adjunct to conventional RA therapies, particularly through dietary counseling.
Monitoring disease activity with validated tools can help evaluate response to microbiome-focused interventions.
Collaboration with nutritionists and microbiome specialists may enhance personalized care.
Further clinical trials are needed to establish evidence-based guidelines for microbiome modulation in RA.
Patient education on diet and lifestyle factors influencing microbiota may support holistic disease management.